Bendamustine and cloretazine: alkylators with sharply contrasting activity in AML.
Giles
Francis J
FJ
Division of Hematology and Medical Oncology, San Antonio, TX 78229, USA. frankgiles@aol.com
D000208:Acute Disease; D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D016296:Mutagenesis / Q000187:drug effects; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*
D018906:Antineoplastic Agents, Alkylating; D006834:Hydrazines; D009588:Nitrogen Mustard Compounds; D013449:Sulfonamides; C483604:laromustine; D000069461:Bendamustine Hydrochloride